Aryl substituted heterocyclyl sulfones

Patent metadata

Field	Value
Publication number	US-9896440-B2
Application number	US-201514685742-A
Country	US
Kind code	B2
Filing date	Apr 14, 2015
Priority date	Apr 14, 2014
Publication date	Feb 20, 2018
Grant date	Feb 20, 2018

Abstract

The invention relates to aryl substituted heterocyclyl sulfones as voltage gated calcium channel blockers, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

First claim

The invention claimed is:

1. A compound of formula (I),

wherein
m represents 0, 1 or 2;
n denotes 0 or 1;
wherein one of m or n is at least 1;
Y is selected from the group consisting of bond and —C(R 3 ) 2 —;
wherein each R 3 is independently selected from the group consisting of H and C 1-6 -alkyl, or two R 3 form together with the C-atom connecting them a C 3-10 -cycloalkyl or a 3 to 7 membered heterocyclyl;

L is —[C(R 4 ) 2 ] x —(X) y —[C(R 4 ) 2 ] z ,
wherein x is 0, 1 or 2, y is 0 or 1 and z is 0 or 1, with the proviso that x≧y;
each R 4 is independently selected from the group consisting of H and C 1-6 -alkyl,
or two R 4 form together with the C-atom connecting them a C 3-10 -cycloalkyl or a 3 to 7 membered heterocyclyl or two R 4 form together with two adjacent C-atoms connecting them a C 3-10 -cycloalkyl or a 3 to 7 membered heterocyclyl,
X is selected from the group consisting of O, S, S(O) 2 , N(H) or N(C 1-6 -alkyl);

R 1 is selected from the group consisting of H; F; Cl; CN; C 1-6 -alkyl; C 1-6 -alkyl-O(R 5 ) and C 1-6 -alkyl-N(R 5 ) 2 ;
wherein each R 5 is independently selected from H or C 1-6 -alkyl or two R 5 form together with the N-atom connecting them a 3 to 7 membered heterocyclyl;

R 2 is selected from the group consisting of H; F; Cl; CN; C 1-6 -alkyl; C 1-6 -alkyl-O(R 6 ) and C 1-6 -alkyl-N(R 6 ) 2 ;
wherein each R 6 is independently selected from H or C 1-6 -alkyl or two R 6 form together with the N-atom connecting them a 3 to 7 membered heterocyclyl;

Ar 1 represents aryl or heteroaryl, wherein said aryl or said heteroaryl is substituted by zero or one or two or three substituents R 7 ,
Ar 2 represents aryl or C 3-10 -cycloalkyl, wherein said aryl or said C 3-10 -cycloalkyl is substituted by zero or one or two or three substituents R 8 ,
wherein each R 7 and each R 8 is independently selected from the group consisting of F; Cl; Br; I; NO 2 ; CN; C 1-6 -alkyl; CF 3 ; CF 2 H; CFH 2 ; CF 2 Cl; CFCl 2 ; C(═O)—H; C(═O)—C 1-6 -alkyl; C(═O)—OH; C(═O)—O—C 1-6 -alkyl; C(═O)—N(H)(OH); C(═O)—NH 2 ; C(═O)—N(H)(C 1-6 -alkyl); C(═O)—N(C 1-6 -alkyl) 2 ; C(═N—OH)—H; C(═N—OH)—C 1-6 -alkyl; C(═N—O—C 1-6 -alkyl)-H; C(═N—O—C 1-6 -alkyl)-C 1-6 -alkyl; OH; OCF 3 ; OCF 2 H; OCFH 2 ; OCF 2 Cl; OCFCl 2 ; O—C 1-6 -alkyl; O—C(═O)—C 1-6 -alkyl; O—C(═O)—O—C 1-6 -alkyl; O—(C═O)—N(H)(C 1-6 -alkyl); O—C(═O)—N(C 1-6 -alkyl) 2 ; O—S(═O) 2 —C 1-6 -alkyl; O—S(═O) 2 —OH; O—S(═O) 2 —O—C 1-6 -alkyl; O—S(═O) 2 —NH 2 ; O—S(═O) 2 —N(H)(C 1-6 -alkyl); O—S(═O) 2 —N(C 1-6 -alkyl) 2 ; NH 2 ; N(H)(C 1-6 -alkyl); N(C 1-6 -alkyl) 2 ; N(H)—C(═O)—C 1-6 -alkyl; N(H)—C(═O)—O—C 1-6 -alkyl; N(H)—C(═O)—NH 2 ; N(H)—C(═O)—N(H)(C 1-6 -alkyl); N(H)—C(═O)—N(C 1-6 -alkyl) 2 ; N(C 1-6 -alkyl)-C(═O)—C 1-6 -alkyl; N(C 1-6 -alkyl)-C(═O)—O—C 1-6 -alkyl; N(C 1-6 -alkyl)-C(═O)—NH 2 ; N(C 1-6 -alkyl)-C(═O)—N(H)(C 1-6 -alkyl); N(C 1-6 -alkyl)-C(═O)—N(C 1-6 -alkyl) 2 ; N(H)—S(═O) 2 OH; N(H)—S(═O) 2 —C 1-6 -alkyl; N(H)—S(═O) 2 —O—C 1-6 -alkyl; N(H)—S(═O) 2 —NH 2 ; N(H)—S(═O) 2 —N(H)(C 1-6 -alkyl); N(H)—S(═O) 2 N(C 1-6 -alkyl) 2 ; N(C 1-6 -alkyl)-S(═O) 2 —OH; N(C 1-6 -alkyl)-S(═O) 2 —C 1-6 -alkyl; N(C 1-6 -alkyl)-S(═O) 2 —O—C 1-6 -alkyl; N(C 1-6 -alkyl)-S(═O) 2 —NH 2 ; N(C 1-6 -alkyl)-S(═O) 2 —N(H)(C 1-6 -alkyl); N(C 1-6 -alkyl)-S(═O) 2 —N(C 1-6 -alkyl) 2 ; SH; SCF 3 ; SCF 2 H; SCFH 2 ; SCF 2 Cl; SCFCl 2 ; S—C 1-6 -alkyl; S(═O)—C 1-6 -alkyl; S(═O) 2 —C 1-6 -alkyl; S(═O) 2 —OH; S(═O) 2 —O—C 1-6 -alkyl; S(═O) 2 —NH 2 ; S(═O) 2 —N(H)(C 1-6 -alkyl); S(═O) 2 —N(C 1-6 -alkyl) 2 ; C 3-10 -cycloalkyl; 3 to 7 membered heterocyclyl; aryl; heteroaryl; O—C 3-10 -cycloalkyl; O-(3 to 7 membered heterocyclyl); O-aryl; O-heteroaryl; C(═O)—C 3-10 -cycloalkyl; C(═O)-(3 to 7 membered heterocyclyl); C(═O)-aryl; C(═O)-heteroaryl; S(═O) 2 —C 3-10 -cycloalkyl; S(═O) 2 -(3 to 7 membered heterocyclyl); S(═O) 2 -aryl; S(═O) 2 -heteroaryl; S(═O)(═NR 13 )—C 3-10 -cycloalkyl; S(═O)(═NR 13 )-(3 to 7 membered heterocyclyl); S(═O)(═NR 13 )-aryl and S(═O)(═NR 13 )-heteroaryl, wherein R 13 represents H or C 1-6 -alkyl;

wherein in each case said C 1-6 -alkyl may be branched or unbranched; unsubstituted or mono- or polysubstituted; and
wherein in each case said C 3-10 -cycloalkyl, 3 to 7 membered heterocyclyl aryl and heteroaryl may be unsubstituted or mono- or polysubstituted;
optionally in the form of a single stereoisomer or a mixture of stereoisomers, in form of the free compound and/or a physiologically acceptable salt and/or a physiologically acceptable solvate thereof.

2. A compound according to claim, wherein the compound of formula (I) is a compound according to formula (II),

or formula (IIa) or (IIb),

wherein each Ar 1 , Ar 2 , R 1 , R 2 , Y and L are defined according to claim 1 .

3. A compound according to claim 1 , wherein the compound of formula (I) is one diastereomer.

4. A compound according to claim 3 , wherein the compound of formula (I) is one enantiomer.

5. A compound according to claim 1 , wherein
R 2 represents H, CH 3 , C 2 H 5 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 OH, CH 2 OCH 3 , CH 2 NH 2 , CH 2 N(H)CH 3 or CH 2 N(CH 3 ) 2 .

6. A compound according to claim 1 , wherein
R 1 represents H, CH 3 , C 2 H 5 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 OH, CH 2 OCH 3 , CH 2 NH 2 , CH 2 N(H)CH 3 or CH 2 N(CH 3 ) 2 .

7. A compound according to claim 1 , wherein Ar 1 represents phenyl or pyridinyl, substituted by zero or one or two or three substituents R 7 ,
wherein each R 7 is independently selected from the group consisting of F; Cl; CN; C 1-6 -alkyl; CF 3 ; CF 2 H; CFH 2 ; C(═O)—C 1-6 -alkyl; C(═O)—OH; C(═O)—O—C 1-6 -alkyl; C(═O)—N(H)(OH); C(═O)—NH 2 ; C(═O)—N(H)(C 1-6 -alkyl); C(═O)—N(C 1-6 -alkyl) 2 ; OH; OCF 3 ; OCF 2 H; OCFH 2 ; OCF 2 Cl; OCFCl 2 ; O—C 1-6 -alkyl; NH 2 ; N(H)(C 1-6 -alkyl); N(C 1-6 -alkyl) 2 ; N(H)—C(═O)—C 1-6 -alkyl; N(C 1-6 -alkyl)-C(═O)—C 1-6 -alkyl; N(H)—S(═O) 2 —C 1-6 -alkyl; SCF 3 ; S—C 1-6 -alkyl; S(═O)—C 1-6 -alkyl; S(═O) 2 —C 1-6 -alkyl; S(═O) 2 —NH 2 ; S(═O) 2 —N(H)(C 1-6 -alkyl); S(═O) 2 —N(C 1-6 -alkyl) 2 ; C 3-10 -cycloalkyl; 3 to 7 membered heterocyclyl; O—C 3-10 -cycloalkyl and O-(3 to 7 membered heterocyclyl).

8. A compound according to claim 1 , wherein Ar 1 is represented by subformula SF-I

wherein
X is CH or N,
R 10 is selected from the group consisting of CF 3 ; CF 2 H; CFH 2 ; OCF 3 ; OCF 2 H and OCFH 2 ;
and R 11 is selected from the group consisting of H; F; Cl; CN; CH 3 ; CH 2 CH 3 ; CH 2 CH 2 CH 3 ; CH(CH 3 ) 2 ; CH(CH 3 )CH 2 CH 3 ; CH 2 CH 2 CH 2 CH 3 ; CH 2 CH(CH 3 ) 2 ; C(CH 3 ) 3 ; CF 3 ; CF 2 H; CFH 2 ; OCF 3 ; OCH 3 ; OCH 2 CH 3 ; OCH(CH 3 ) 2 ; S(═O)—CH 3 and S(═O) 2 —CH 3 .

9. A compound according to claim 1 , wherein L is bond, CH 2 ; C(CH 3 ) 2 ; CH(CH 3 ); CH 2 CH 2 ; CH 2 C(CH 3 ) 2 ; C(CH 3 ) 2 CH 2 ; CH 2 O; C(CH 3 ) 20 ; CH(CH 3 )O;

10. A compound according to claim 1 , wherein Ar 2 represents phenyl, substituted by one or two substituents R 8 ,
wherein each R 8 is independently selected from the group consisting of F; Cl; CN; C 1-6 -alkyl; CF 3 ; CF 2 H; CFH 2 ; OCF 3 ; OCF 2 H; OCFH 2 ; O—C 1-6 -alkyl; S—C 1-6 -alkyl; S(═O)—C 1-6 -alkyl; S(═O) 2 —C 1-6 -alkyl; C 3-10 -cycloalkyl; 3 to 7 membered heterocyc

Assignees

• Gruenenthal Gmbh

Inventors

• Schunk Stefan
• Reich Melanie
• Jakob Florian
• Koenigs Rene Michael
• Damann Nils
• Haurand Michael
• Rogers Marc
• Mackenzie Kathy
• Hamlyn Richard

Classifications

• C07D405/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D413/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P25/08

  Antiepileptics; Anticonvulsants · CPC title

• A61P25/00 Primary

  Drugs for disorders of the nervous system · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title